Key Takeaways J&J will report third-quarter 2025 results on Oct. 14, kicking off the earnings season for pharma players.Sales growth is expected from Darzalex, Tremfya, Erleada and new drugs like Carvykti and Tecvayli.Stelara faces steep biosimilar competition, while MedTech faces China-related headwinds.Johnson & Johnson (JNJ) will begin the earnings season for the drug & biotech sector when it reports its third-quarter 2025 results on Oct. 14. The Zacks Consensus Estimate for third-quarter sales and earni ...

Johnson & Johnson is set to release its quarterly earnings with an estimated EPS of $2.78 and projected revenue of $23.7 billion.The company's stock has increased by 31% this year, outperforming the S&P 500's 14% rise.JNJ has a history of outperforming earnings estimates, with an average earnings surprise of 5.96% over the last two quarters.Johnson & Johnson (NYSE:JNJ) is a leading global healthcare company known for its wide range of products, including pharmaceuticals, medical devices, and consumer health ...

Key Takeaways Pfizer's deal with Trump cuts drug prices, boosts U.S. investment and lifts pharma sector sentiment.Investor optimism grows as major drugmakers eye similar tariff-free pricing agreements with Trump.J&J, Bayer and Novartis show strong growth momentum, making them attractive pharma investment picks.Late last month, Pfizer (PFE) announced a landmark deal with the Trump administration to cut drug prices and expand U.S. innovation and manufacturing.Under the deal, Pfizer agreed to slash prices of s ...

Key Takeaways J&J projects stronger Innovative Medicine sales in H2 despite Stelara's LOE.Higher demand for Darzalex, Tremfya, and Erleada likely supported segment growth in Q3.Stelara biosimilars and IRA's Part D redesign continue to put pressure on J&J's drug sales.Johnson & Johnson (JNJ) , through its Innovative Medicine division, markets several blockbuster drugs across diverse therapeutic areas, including neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary hypertension (PH), an ...

Summary of Option Care Health Conference Call Company Overview - **Company**: Option Care Health (NasdaqGS: OPCH) - **Industry**: Home and alternate site infusion therapy - **Key Facts**: - Largest provider of infusion services in the U.S. - Serves over 300,000 unique patients annually - Employs approximately 8,000 team members, with over 4,000 being clinicians - Licensed in all 50 states with over 90 pharmacies for compounding and distribution [4][5] Core Business Insights - **Service Focus**: High-quality care at an appropriate cost, addressing the high cost of healthcare while maintaining clinical outcomes [5][7] - **Market Demand**: Strong relationships with referral sources (hospitals, clinics) to capture demand across acute and chronic portfolios [5][6] - **Growth Drivers**: - High single-digit organic top-line growth and low double-digit adjusted EBITDA growth expected to continue [9][10] - Combination of low single-digit growth in acute care and faster-growing low double-digit growth in chronic care [10] Financial Performance - **Revenue Growth**: Anticipated growth driven by innovation, new disease prevalence, and partnerships with pharmaceutical companies [10][11] - **Gross Profit**: Expected to grow at a slower rate than revenue due to a mix shift towards chronic care, but still contributing positively to gross margin [11] - **Adjusted EPS**: New disclosures indicate expected growth in adjusted EPS due to strong cash generation [12] Market Dynamics - **Private Equity Activity**: Increased interest in home infusion services, indicating a competitive and capital-rich environment [6] - **Biosimilars**: Seen as an opportunity for upside, providing leverage for better acquisition costs despite lower margins [29][30] Challenges and Risks - **Stelara Drug Economics**: Expected impact of $60-70 million in 2025 due to changes in reimbursement and inventory management [21][24] - **Market Share**: Despite strong performance, there is still market share to capture, requiring ongoing local execution and partnerships [13][14] Strategic Initiatives - **Advanced Practitioner Model**: Aimed at expanding access for Medicare beneficiaries and enhancing clinical oversight for complex patients [33][36] - **M&A Strategy**: Focused on disciplined capital deployment for growth, with potential acquisitions to enhance market presence [43][44] Future Outlook - **Growth Expectations**: Anticipated reversion to historical growth rates post-competitive exits, with continued focus on capturing market demand [41] - **Cash Flow Generation**: Projected over $320 million in cash flow from operations, providing opportunities for shareholder-friendly capital deployment [45][46] Conclusion - **Execution Capability**: The company emphasizes its ability to execute consistently and maintain a durable business model, positioning itself well for future growth [45][46]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. “I am delighted to welcome Ted to the key role of Lead Independent Director,” said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. “Ted has ex ...

Key Takeaways AbbVie projects revenue growth in 2025 despite Humira sales falling by over 54% in the first half of 2025.Skyrizi and Rinvoq are fueling gains with new launches, head-to-head data and expanding indications.AbbVie is also expanding in oncology and neuroscience, adding new drugs and boosting migraine uptake.AbbVie (ABBV) expects to return to robust revenue growth in 2025, despite the U.S. loss of exclusivity (LOE) for its flagship drug Humira over two years ago. The drug, which went off-patent i ...

Johnson & Johnson FY Conference Summary Company Overview - **Company**: Johnson & Johnson (NYSE: JNJ) - **Date of Conference**: September 24, 2025 - **Speaker**: Tom Cavanaugh, Company Group Chairman, Johnson & Johnson Innovative Medicine North America Key Points Business State and Growth Outlook - Johnson & Johnson is entering a new era of growth in the innovative medicine sector, overcoming the loss of exclusivity of its major asset, Stelara [4][5] - The company anticipates a compound annual growth rate (CAGR) of 5% to 7% through the remainder of the decade, with confidence leaning towards the upper range of this projection [6][7] Recent Product Launches and Pipeline - Recent approvals include TAR 200 for bladder cancer and Caplyta for adjunctive major depressive disorder, with the latter expected to significantly contribute to growth [5][6] - Tremfya, launched for inflammatory bowel disease (IBD), is projected to exceed $10 billion in sales, driven by its unique administration method and strong market reception [19][20] - Rybrevant for non-small cell lung cancer is also expected to reach over $5 billion in peak sales, supported by positive clinical data [21][22] Market Dynamics and Policy Environment - The company has raised its guidance amidst various macroeconomic challenges, indicating confidence in its ability to navigate policy uncertainties [11][12] - Johnson & Johnson is committed to $55 billion in U.S. manufacturing, aligning with government initiatives to boost domestic production [13][14] Oncology and Immunology Insights - Darzalex, a foundational therapy for multiple myeloma, is expected to continue its growth trajectory, with significant survival rate improvements reported [41][42] - The company is optimistic about the potential of Carvykti, a CAR-T therapy, to achieve over $5 billion in peak sales, especially with recent data showing long-term remission in patients [43][46] Neuroscience Developments - Spravato has shown strong growth, with a unique profile that allows for rapid efficacy in treatment-resistant depression [71][72] - Caplyta is anticipated to become a $5 billion asset, with a focus on its efficacy and minimal side effects compared to traditional treatments [74][77] Research and Development Strategy - Johnson & Johnson emphasizes a strong commitment to R&D, focusing on oncology, immunology, and neuroscience, while leveraging AI for efficiency [82] - The company is open to M&A opportunities, particularly in adjacent therapeutic areas, to enhance its portfolio [83] Future Opportunities - The company is exploring new modalities such as cell therapy and gene editing, with a focus on disease area strategies rather than specific modalities [85] - There is a strong emphasis on integrating MedTech capabilities with pharmaceutical innovations, as seen with TAR 200 [89] Additional Insights - The company is actively addressing the disconnect between market expectations and its growth potential, particularly in oncology and neuroscience [58][78] - Johnson & Johnson is committed to transparency in pricing and reducing healthcare costs through policy engagement and reform [15][16] This summary encapsulates the key insights and strategic directions discussed during the conference, highlighting Johnson & Johnson's robust growth outlook and innovative product pipeline.

Johnson & Johnson (NYSE:JNJ) is included among the 12 Best Dividend Paying Stocks to Buy Now. Johnson & Johnson’s (JNJ) Dividend Growth Record Strengthens its Role in Dividend Paying Stocks Johnson & Johnson (NYSE:JNJ) is a major player in the pharmaceutical and medical device industries, with a recent market value close to $425 billion. The company is also showing growth, as second-quarter revenue increased 5.8% from the previous year and earnings rose 18%. Until 2023, Johnson & Johnson (NYSE:JNJ) oper ...